Weekly News Round-up – 19/2/21


PFIZER AND MODERNA VACCINES LESS POTENT AGAINST AGGRESSIVE COVID VARIANTS – Further evidence has arisen suggesting Pfizer and its partner BioNTech must update their current vaccines to defeat newer variants of COVID-19. In a letter published in the New England Journal of Medicine, Pfizer said its vaccine appeared around two thirds less potent against the South African variant than against the initial virus. Against a full panel of mutations, including the Denmark and UK variants, they found a sixfold decrease in neutralising antibodies. Analysts examining the data predicted “significant numbers of breakthrough cases in vaccinated individuals” to the South African variant.
NOVAVAX STRIKES 1.1 BILLION DOSE VACCINE DEAL WITH VACCINE ALLIANCE – A memorandum of understanding has been signed between COVID-19 vaccine maker Novavax and Gavi the Vaccine Alliance for 1.1 billion doses of Novavax’s vaccine to be supplied to COVAX, the global collaboration ensuring equitable access to vaccines. Under the COVAX agreement, Novavax expects to provide doses for high-income markets, while the Serum Institute will manufacture doses for other countries.
PRESIDENT BIDEN TO PROVIDE $1.6 BILLION FOR IMPROVED COVID TESTING – The Biden administration is set to provide $1.6 billion in order to expand and improve COVID-19 testing and sequencing. The government announced regional co-ordinating centres will be set up to identify lab testing capacities and match them to specific areas of need. The government has pledged to invest $815 million to build US manufacturing of testing supplies. The US Centers for Disease Control and Prevention will also invest around $200 million to expand genomic sequencing for the virus and detect emerging variants.
In other news:
R&D
GSK expanding COVID antibody collaboration with VIR to include possible flu therapies
Clinical
UK gives approval to controversial COVID-19 vaccine trials
Manufacturing
AZ’s Mexico vaccine partner forced to overhaul factory, slowing production
EU orders further 200 million doses of Pfizer/BioNTech COVID vaccine
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years agoThe Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years ago
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years agoIntrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years ago